ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best cheap stocks under $10 to buy in June. On May 4, ADMA Biologics received ...

Outlook Therapeutics gains for the third consecutive session on the U.S. Food and Drug Administration’s (FDA) approval for ...

The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of ...

Wockhardt’s stock hit a record high after the US FDA approved its novel superbug-fighting antibiotic Zaynich for complicated ...

Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott ...

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks ...

– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer ...

Shares of Wockhardt surged over 19% to hit a fresh record high on Monday after the pharmaceutical company secured approval ...

Natera gets a buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue ...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

The biotech group has struggled as a whole in 2025, but analysts say the innovation that has always supported the biotech ...